Etracker Debug:
	et_pagename = "Biological Chemistry|bchm|C|[EN]"
	
        
Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year

VolumeIssuePage

Issues

Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer

Mona Mostafa Mohamed1 / Dora Cavallo-Medved2 / Bonnie F. Sloane3

1Department of Zoology, Faculty of Science, Cairo University, 12613 Cairo, Egypt

2Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA and Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA

3Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA and Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA

Corresponding author

Citation Information: Biological Chemistry. Volume 389, Issue 8, Pages 1117–1121, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: 10.1515/BC.2008.117, August 2008

Publication History

Received:
2007-12-14
Accepted:
2008-04-07
Published Online:
2008-08-19

Abstract

Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, and here, we examined in vitro the interactions between the human IBC cell line SUM149 and U937 human naive monocytes. We found an altered morphology, enhanced invasiveness and proteolytic activity of SUM149 cells when cultured with U937 cells or in U937-conditioned media (U937-CM). Increases in expression and activity of the cysteine protease cathepsin B and expression of caveolin-1 were also detected in SUM149 cells grown in U937-CM, thus suggesting a contribution of these proteins to the augmented invasion through and proteolysis of the extracellular matrix by the IBC cells.

Keywords: cathepsin B; caveolin-1; co-culture; extracellular matrix; proteolysis

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.